Measles surveillance in Canada, 2019.

measles measles elimination surveillance travel health vaccination

Journal

Canada communicable disease report = Releve des maladies transmissibles au Canada
ISSN: 1188-4169
Titre abrégé: Can Commun Dis Rep
Pays: Canada
ID NLM: 9303729

Informations de publication

Date de publication:
31 Mar 2021
Historique:
entrez: 20 5 2021
pubmed: 21 5 2021
medline: 21 5 2021
Statut: epublish

Résumé

The Public Health Agency of Canada (PHAC) has conducted enhanced measles surveillance since 1998, the year endemic measles transmission was eliminated in Canada. The objective of this annual national measles surveillance report is to provide an epidemiologic summary of measles activity reported in Canada for 2019 in order to provide evidence to support the continued verification of Canada's measles elimination status. Measles surveillance data are housed in the Canadian Measles and Rubella Surveillance System (CMRSS) database. Descriptive analyses of demographics and risk factors were performed. Outbreak characteristics were summarized and genotypic analyses conducted. Surveillance, laboratory and vaccine coverage data for 2019 were used to assess Canada's status against the Pan American Health Organization (PAHO) essential criteria for the verification of measles elimination. In 2019, 113 measles cases were reported in Canada (crude incidence rate of 3.0 cases per 1,000,000 population). Of these cases, 42 (37%) were imported into Canada, and of the imported cases, 12 (29%) resulted in further transmission. Infants younger than one year had the highest age-specific incidence rate at 13.1 cases per 1,000,000 population. Only 29% of cases had one or more documented doses of measles-containing vaccine. One-fifth (19%) of cases were hospitalized; no deaths were reported. Genotype information was available for 100% of outbreaks reported in 2019 and 90% of non-outbreak-related measles cases; of cases with genotype information available, 27% were B3 and 73% were D8. Despite meeting/partially meeting only three out of four of PAHO's essential criteria for measles elimination status, there is no evidence that endemic measles transmission has been reestablished in Canada.

Sections du résumé

BACKGROUND BACKGROUND
The Public Health Agency of Canada (PHAC) has conducted enhanced measles surveillance since 1998, the year endemic measles transmission was eliminated in Canada. The objective of this annual national measles surveillance report is to provide an epidemiologic summary of measles activity reported in Canada for 2019 in order to provide evidence to support the continued verification of Canada's measles elimination status.
METHODS METHODS
Measles surveillance data are housed in the Canadian Measles and Rubella Surveillance System (CMRSS) database. Descriptive analyses of demographics and risk factors were performed. Outbreak characteristics were summarized and genotypic analyses conducted. Surveillance, laboratory and vaccine coverage data for 2019 were used to assess Canada's status against the Pan American Health Organization (PAHO) essential criteria for the verification of measles elimination.
RESULTS RESULTS
In 2019, 113 measles cases were reported in Canada (crude incidence rate of 3.0 cases per 1,000,000 population). Of these cases, 42 (37%) were imported into Canada, and of the imported cases, 12 (29%) resulted in further transmission. Infants younger than one year had the highest age-specific incidence rate at 13.1 cases per 1,000,000 population. Only 29% of cases had one or more documented doses of measles-containing vaccine. One-fifth (19%) of cases were hospitalized; no deaths were reported. Genotype information was available for 100% of outbreaks reported in 2019 and 90% of non-outbreak-related measles cases; of cases with genotype information available, 27% were B3 and 73% were D8.
CONCLUSION CONCLUSIONS
Despite meeting/partially meeting only three out of four of PAHO's essential criteria for measles elimination status, there is no evidence that endemic measles transmission has been reestablished in Canada.

Identifiants

pubmed: 34012339
doi: 10.14745/ccdr.v47i03a05
pii: 470305
pmc: PMC8109285
doi:

Types de publication

Journal Article

Langues

eng

Pagination

149-160

Déclaration de conflit d'intérêts

Competing interests: None.

Références

Hum Vaccin Immunother. 2019;15(12):2856-2864
pubmed: 31184979
Can Commun Dis Rep. 2020 Apr 02;46(4):77-83
pubmed: 32558823
Can Commun Dis Rep. 2015 Jul 02;41(7):157-168
pubmed: 29769947
J Infect Dis. 2011 Sep 1;204 Suppl 2:S683-9
pubmed: 21954267
Can Commun Dis Rep. 2013 Oct 30;39(ACS-3):1-52
pubmed: 31696866
MMWR Morb Mortal Wkly Rep. 2019 Dec 06;68(48):1105-1111
pubmed: 31805033
Ann Epidemiol. 1992 Nov;2(6):805-12
pubmed: 1342333
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
Wkly Epidemiol Rec. 2015 Jul 24;90(30):373-80
pubmed: 26211016
MMWR Morb Mortal Wkly Rep. 2018 Nov 30;67(47):1323-1329
pubmed: 30496160
J Infect Dis. 2011 Jul;204 Suppl 1:S514-23
pubmed: 21666208
MMWR Morb Mortal Wkly Rep. 2015 Oct 02;64(38):1088-92
pubmed: 26421903
J Infect Dis. 2004 May 1;189 Suppl 1:S236-42
pubmed: 15106117
Wkly Epidemiol Rec. 1998 Aug 28;73(35):265-9
pubmed: 9745371

Auteurs

Cameron Coulby (C)

Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.

Francesca Reyes Domingo (FR)

Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.

Joanne Hiebert (J)

National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB.

Susan G Squires (SG)

Centre for Immunization and Respiratory Infectious Diseases, Public Health Agency of Canada, Ottawa, ON.

Classifications MeSH